Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 166, Issue 8, 2002, Pages 1084-1091

  Mahler, Donald A ^a,b   Wire, Patrick ^a,b   Horstman, Donald ^a,b   Chang, Chai Ni ^a,b   Yates, Julie ^a,b   Fischer, Tracy ^a,b   Shah, Tushar ^a,b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

2 agonist; Chronic obstructive pulmonary disease; Inhaled corticosteroid; Transition Dyspnea Index

Indexed keywords

FLUTICASONE PROPIONATE; SALBUTAMOL; SALMETEROL; ANDROSTANE DERIVATIVE; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DRUG DERIVATIVE; FLUTICASONE; FLUTICASONE PROPIONATE - SALMETEROL COMBINATION; FLUTICASONE PROPIONATE SALMETEROL COMBINATION; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HEART ARRHYTHMIA; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; THRUSH; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; NEBULIZER; PATHOPHYSIOLOGY; PEAK EXPIRATORY FLOW; POWDER; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, TOPICAL; ADRENERGIC BETA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PEAK EXPIRATORY FLOW RATE; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 0037108632     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.2112055     Document Type: Article

References (33)

1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-S120.
2. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276.
3. Postma DS, Kerstjens HA. Are inhaled glucocorticosteroids effective in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 1999;160:S66-S71.
4. Thompson AB, Mueller MB, Heires AJ, Bohling TL, Daughton D, Yancey SW, Sykes RS, Rennard SI. Aerosolized beclomethasone in chronic bronchitis. Am Rev Respir Dis 1992;146:389-395.
5. Llewellen-Jones CG, Hams AT, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996;153:616-621.
6. Confalonieri M, Mainardi E, Della Porta R, Bernorio S, Gandola L, Beghe B, Spanevello A. Inhaled corticosteroids reduce neutrophilic inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998;53:583-585.
7. Balbi B, Majori M, Bertacco S, Convertino G, Cuomo A, Donner CF, Pesci A. Inhaled corticosteroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation? Chest 2000;117:1633-1637.
8. Yildiz F, Kaur AC, Ilgazli A, Celikoglu M, Kacar Ozkara S, Paksoy N, Ozkarakas O. Inhaled corticosteroids may reduce neutrophilic inflammation in patients with stable chronic obstructive pulmonary disease. Respiration 2000;67:71-76.
9. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicenter randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-780.
10. Pauwles RA, Lofdahl C-G, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-1953.
11. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fiuticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-1303.
12. Wise R, Connett J, Weinmann G, Scanlon P, Skeans M. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease: The Lung Health Study Research Group. N Engl J Med 2000;343:1902-1909.
13. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984;85:751-758.
14. Petty TL. The national mucolytic study: results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990;97:75-83.
15. Rubin BK, Ramirez O, Ohar JA. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest 1996;109:348-352.
16. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung diseases. Thorax 1987;42:773-778.
17. Prescribing information for Cortrosyn for injection. Organon Inc., West Orange, NJ.
18. van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 1958;37:351-361.
19. Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the Transition Dyspnea Index. J Clin Epidemiol (In press)
20. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-965.
21. Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K. Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163: 1087-1092.
22. Cazzola M, Di Lorenzo G, Di Perna F, Calderaro F, Testi R, Centanni S. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest 2000;118:1576-1581.
23. Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997;112:336-340.
24. Casaburi R, Mahler D, Jones PW, Wanner A, San Pedro G. ZuWallack RL, Menjoge SS, Serby CW, Witek T. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-224.
25. Vincken W, van Noord JA, Greefhorst APM, Bantje TA, Kesten S, Korducki L, Cornelissen PJG. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-216.
26. ZuWallack RL, Mahler DA, Reilly, Church N, Emmett A, Rickard K, Knobil K. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1628-1630.
27. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:967-975.
28. O'Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:1557-1565.
29. O'Donnell DE. Exertional breathlessness in chronic respiratory disease. In: Mahler DA, editor. Dyspnea. New York: Marcel Dekker; 1998. p. 97-148.
30. Ayers ML, Mejia R, Ward J, Lentine T, Mahler DA. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur Respir J 2001;17:1132-1137.
31. Baird JC, Noma E. Fundamentals of scaling and psychophysics. New York: Wiley Interscience; 1978.
32. Mahler DA, Tomlinson D, Olmstead EM, Tosteson ANA, O'Connor GT. Changes in dyspnea, health status, and lung function in chronic airway disease. Am J Respir Crit Care Med 1995;151:61-65.
33. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-1289.